Subscribe To
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS Target Enrollment Achieved in Phase 3 Pivotal Study of ANX005 in GBS Representing the Company’s Third Successfully Executed Clinical Study in GBS Company on Track to Report Pivotal Data in the First Half of 2024 BRISBANE, Calif., Oct. 10, 2023 […] The post Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS) appeared first on ForexTV...
Read More
Posted: Oct 10 2023, 10:30
Author Name: forextv
Views: 112245